ABBV-400 for Advanced Solid Tumors

Purpose of this Study

We are doing this study to find the best dose of the study drug, ABBV-400, and to see if it is a safe and effective option for treating cancer.

Who Can Participate?

Eligibility

Adults ages 18+ who:<ul>
<li>Are diagnosed with an advanced form of cancer</li>
<li>Have not seen improvement from standard therapies</li></ul>
For more information about who can join this study, please contact the study team at 919-668-1861.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

If you choose to join this study, you will:<ul>
<li>Get IV infusions of the study drug every 3 weeks for up to 2 years</li>
<li>Give blood and urine samples</li>
<li>Have regular CT or MRI scans</li></ul>

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

[M21-404] A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 in adult subjects with advanced solid tumors

Principal Investigator

John
Strickler

Protocol Number

PRO00111582

NCT ID

NCT05029882

Phase

I

Enrollment Status

Open to Enrollment